On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials. Dr. Jason Karlawish joins the podcast to discuss the recent proposal, share his reaction to the decision, and tell us how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future.
Guest: Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania
Episode Topics1:48 What’s the difference between the FDA and Centers for Medicare and Medicaid Services?
3:58 What is the purpose of sharing a proposal and allowing public comment after? Is it possible the proposal could change?
9:09 What are your key takeaways from the CMS proposal?
11:58 Who’s being charged the cost of the treatment if it is part of a clinical trial?
18:33 What does this decision, with its focus on research often occurring in major urban medical centers, mean for equity and access?
26:27 What is the future of Alzheimer’s disease research after the CMS decision?
Show NotesRead the Center for Medicare and Medicaid Services’s press release about the proposed coverage policy, view submitted public comments about the decision, and submit your own comment.
Learn more about Dr. Jason Karlawish’s work and writing at his website.
Listen to our four-part episode series with Dr. Jason Karlawish about his book, The Problem of Alzheimer’s, on our website (episode 1, episode 2, episode 3, episode 4).
Alcohol and the Brain: One Drink a Day Associated with Brain Shrinkage
Women’s Health Month: Women and Alzheimer’s Disease
Disaggregating Racial Data: How Studying Ethnic Subgroups Can Improve Research
Incorporating Cultural Knowledge: Improving Alzheimer’s Disease Research for Veterans and Native Americans
Update on Blood Tests for Alzheimer’s Disease
Harnessing the Power of Autophagy to Treat Alzheimer’s Disease
Go with the (4D) Flow: Neuroimaging Technology Used to Study Overlap of Cerebrovascular Disease and Alzheimer’s
Nasal Vaccine for Alzheimer’s Disease Enters Clinical Trial
‘American Dementia’: Author Interview with Dr. Daniel George and Dr. Peter Whitehouse
New Research Shifts Thinking on Metabolism and Aging
Aging Behind the Wheel: How Driving Behavior Can Identify Preclinical Alzheimer’s Disease
Global Challenges in Dementia Diagnosis: A Deep Dive into ADI’s World Alzheimer’s Report 2021
Accessibility and Community: Bringing Alzheimer’s and Dementia Resources to the Latinx Community
You Are What You Eat: Study of Diet and Brain Health Shows Cognitive Benefits from Cheese, Wine and Lamb
AARP Study Shows Stigma Surrounding Dementia among Healthcare Professionals and General Public
Caregivers, Care Partners and People with Dementia: Brainstorming New Interventions for Dementia Care
Tackling Stigma and Alzheimer’s Disease within the AAPI Community
Creative Care: The Power of Imagination in Dementia Caregiving
Better Now than Never: Quit Smoking to Reduce Your Risk for Alzheimer’s Disease
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Life in the A-Zone
Caregiver Storyteller - About Alzheimer’s and Dementia Caregiving
The Life, Love, and Alzheimer’s Podcast
Fading Memories: Alzheimer’s/Dementia Caregiver Support
Alzheimer’s Speaks